在位内膜,Eutopic endometrium
1)Eutopic endometrium在位内膜
1.Effects of progestin and/or GnRHa on mRNA expression of VEGFs in eutopic endometrium with endometriosis;体内外孕激素和GnRHa对子宫内膜异位症患者在位内膜血管内皮生长因子表达影响的差异
2.Specific expression and significance of endocrine gland-derived vascular endothelial growth factor in both eutopic endometrium and the nude mice model of endometriosis;内分泌腺体来源的血管内皮生长因子在子宫内膜异位症在位内膜及裸鼠模型中的特异性表达及意义
3.Objective To investigate the apoptosis-related mechanisms of levenorgestrel-releasing intrauterine system(LNG-IUS),oral medroxyprogesterone(MPA),and injective gonadotrophic hormone releasing hormone agonist(GnRHa)on eutopic endometrium of patients with endometriosis.目的探讨药物治疗,包括左炔诺孕酮宫内节育系统(LNG-IUS)、口服甲羟孕酮(MPA)或注射促性腺激素释放激素类似物(GnRHa)对子宫内膜异位症患者在位内膜凋亡的的影响。
英文短句/例句

1.Nitric Oxide Synthase Expression in Eutopic and Ectopic Endometrial of Women with Endometriosis;NOS在子宫内膜异位症患者在位内膜和异位内膜中的表达
2.Expression of COX-2, PGE_2 and VEGF in Ectopic and Eutopic Endometrium in with Endometriosis and Its Receptors in Ovarian Carcinoma Ascites and Tissue and Its Meaning;COX-2、PGE_2及VEGF在子宫内膜异位症患者异位和在位内膜组织中的表达
3.The Expression of Survivin and MMP-9 and Their Relationship in Eutopic Endometrium of Endometriosis;survivin与MMP-9在子宫内膜异位症在位内膜中表达意义及相关性研究
4.The Expression of Angiopoietin-2, Tie-2 and ER-α in Eutopic Endometrium of EndometriosisAng-2、Tie-2与ER-α在子宫内膜异位症在位内膜中的表达及意义
5.The Study of IL-18, VEGF and MMP-2 on Eutopic Endometrium in Endometriosis;IL-18、VEGF、MMP-2与子宫内膜异位症患者子宫在位内膜的相关研究
6.The Effect from Chinese Materia Medica of Warming Kidney and Dispersing Blood Stasis on Stroma-cell of IM in Endometriosis;温肾化瘀中药对子宫内膜异位症在位内膜间质细胞模型的影响
7.A Method for Primary Culture of Human Eutopic Endometrial Stromal Cells人子宫内膜异位症在位内膜间质细胞原代培养方法探讨
8.Study on the Implanting Ability of the Eutopic Endometrium in Endometriosis with Mice Model利用小鼠模型研究子宫内膜异位症者在位内膜种植能力
9.endometriosis externa外在性子宫内膜异位症;子宫外子宫内膜异位症
10.Expression of polo-like kinase 1 in the ectopic and eutopic endometrial tissue from women with endometriosisPolo-样激酶1在子宫内膜异位症患者在位和异位子宫内膜中的表达
11.Expression of Human β Defensin-2 in Eutopic and Ectopic Endometrium of Women with Endometriosis子宫内膜异位症患者在位和异位内膜组织中人β防御素-2的表达
12.Expression of MIP-1β and LIF in Eutopic Endometrium during Implantation Window in EndometriosisMIP-1β与LIF在子宫内膜异位症窗口期在位子宫内膜的表达
13.Expression of c-fos and integrin-β_3 in eutopic endometrium during implantation window in endometriosisC-fos和整合素β_3在子宫内膜异位症窗口期在位子宫内膜的表达
14.S100A4 expression in the eutopic and ectopic endometria from women with and without endometriosisS100A4在子宫内膜内异症患者在位、异位子宫内膜及正常人子宫内膜组织中的表达
15.Endometriosis: Disorder of the female reproductive system in which endometrium (uterine lining) grows in an abnormal location子宫内膜异位症: 女性生殖系统疾病,子宫内膜生长在异常位置。
16.Expression and Regulation of Galectin-3 in the Patients with Endometriosis;Galectin-3在子宫内膜异位症的表达及调节
17.The Expression and Significance of C-kit in Ectopic Endometrium;C-kit在异位子宫内膜中的表达及意义
18.Expression of VEGF and EG-VEGF in Endometriosis;VEGF和EG-VEGF在子宫内膜异位症的表达
相关短句/例句

ectopic and eutopic endometrium异位和在位内膜
1.Objective: To explore the different influence and mechanism of Neyikangfu suppository (NYKFS) in ectopic and eutopic endometrium of endometriosis model rats by treatment of rectal administration.目的:探讨内异康复栓直肠给药对EMT模型大鼠异位和在位内膜的不同影响和作用机理。
3)Determinant of uterineeutopic endometrium在位内膜决定论
4)Eutopic endometrial stromal cells在位内膜间质细胞
5)Ectopic endometrium异位内膜
1.Effect of danazol on rat ectopic endometrium;丹那唑对子宫内膜异位症大鼠异位内膜的影响
2.Objectives: To study the expression and steroidal regulation of integrinα_5 and integrinβ_3 in eutopic endometrium and ectopic endometrium ,and to investigate the effects of estradiol、progesterone、anti- estradiol and anti-progesterone on the expression of integrinα_5、β_3mRNA in cultured human endometriotic cells in vitro.目的:探讨整合素在子宫内膜异位症在位内膜和异位内膜中的表达及其性激素依赖性,并研究雌激素、孕激素、抗雌激素制剂、抗孕激素制剂对体外培养的人异位子宫内膜细胞整合素α_5、β3mRNA表达的影响,寻求整合素在子宫内膜异位症发生发展过程中的作用,为临床诊断和治疗该疾病做进一步努力。
3.Objective: To investigate the expression of the tissue inhibitor of metalloproteinase-2 in the eutopic and ectopic endometrium from women with and without endometriosis, there by to determine the role of the tissue inhibitor of metalloproteinase-2 (TIMP-2) in the pathogenesis of endometriosis.TIMP-2mRNA在子宫内膜异位症异位内膜和在位内膜组织中均低表达,其相对表达量分别为(0。
6)Eutopic endometrium异位内膜
1.Objective To study the expression patterns of ER and P450arom in the ectopic and eutopic endometrium with adenomyosis and the normal endometrium without estrogen-dependent disorders.结果 ① 在腺肌病患者的在位和异位内膜、正常子宫内膜中均检测到了ER和P450arom的表达:② 在各组内,腺上皮细胞和间质细胞相比,ER和P450arom表达无差异(P>0。
延伸阅读

子宫内膜癌腔内放射治疗子宫内膜癌腔内放射治疗 子宫内膜癌腔内放疗有:①传统方法,使用治疗子宫颈癌的治疗容器,如宫腔管及阴道容器,(容器有:斯德哥尔摩盒式、巴黎弓形、曼彻斯特卵圆形、北京型等)。其缺点是子宫角部受量不足;②Heyman倡导宫腔填充法,将含有镭或其他同位素的金属小囊填满于子宫腔内,使宫腔各壁均能得到高剂量照射,可使单纯放疗效果由30%~40%增至60%以上;③腔内后装放射治疗。剂量:现在采用高剂量率及中剂量率,摒弃低剂量率。高剂量率:Ⅰ期:A点(位于子宫旁三角区内,代表宫旁正常组织受量)总剂量36~40Gy,F点(位于宫腔放射源的顶端旁开子宫中轴2cm,代表肿瘤部受量)总剂量40~45Gy。腔内治疗分5~6次进行,每周1次,每次剂量大致相同。Ⅱ期~Ⅲ期:A点及F点总剂量均为45~50Gy,腔内治疗分6~7次,每周1次,每次剂量大致相同。中剂量率:Ⅰ期:A点总剂量率45~50Gy,F点总剂量50~55Gy,腔内治疗6~8次,每周1次,每次剂量基本相似,Ⅱ~Ⅲ期:A点及F点剂量均为55~60Gy,腔内治疗7~8次,每周1次,每次剂量大致相同。腔内照射多用137Cs、60Co等。